Identification of the aromatase inhibitors anastrozole and exemestane in human urine using liquid chromatography/tandem mass spectrometry

Gespeichert in:
Bibliographische Detailangaben
Deutscher übersetzter Titel:Identifizierung der Aromataseinhibitoren Anastrozol und Exemestan im menschlichen Urin durch Flüssigkeitschromatographie/Tandem-Massenspektrometrie
Autor:Mareck, Ute; Geyer, Hans; Guddat, Sven; Haenelt, Nadine; Koch, Anja; Kohler, Maxie; Opfermann, Georg; Thevis, Mario; Schänzer, Wilhelm
Erschienen in:Rapid communications in mass spectrometry
Veröffentlicht:20 (2006), 12, S. 1954-1962, Lit.
Format: Literatur (SPOLIT)
Publikationstyp: Zeitschriftenartikel
Medienart: Gedruckte Ressource
Sprache:Englisch
ISSN:0951-4198, 1097-0231
DOI:10.1002/rcm.2545
Schlagworte:
Online Zugang:
Erfassungsnummer:PU201109007982
Quelle:BISp

Abstract

Anastrozole (2,2′-[5-(1H-1,2,4-triazol-1-ylmethyl)-1.3-phenylene]bis(2-methylpropionitrile)) and exemestane (6-methylenandrostan-1,4-diene-3,17-dione) are therapeutically used to treat hormone-sensitive breast cancer in postmenopausal women. For doping purposes they may be used to counteract adverse effects of an extensive abuse of anabolic androgenic steroids (gynaecomastia) and to increase plasma testosterone concentrations. Excretion study urine samples and spot urine samples from women suffering from metastatic breast cancer, being treated with anastrozole or exemestane, were collected and analyzed to develop/optimize a detection system for anastrozole and exemestane to allow the identification of athletes who do not comply with the internationally prohibited use of these cancer drugs. The assay was based on liquid-liquid extraction after enzymatic hydrolysis following liquid chromatography/tandem mass spectrometry (LC/MS/MS). Anastrozole, exemestane and its main metabolite (17-dihydroexemestane) were identified in urine by comparison of mass spectra and retention times with respective reference substances. An assay validation for the analysis of anastrozole and exemestane was performed regarding lower limits of detection (anastrozole: 0.02 ng/mL; exemestane: 3.1 ng/mL; dihydroexemestane: 0.5 ng/mL), interday precisions (6.6–11.1%, 4.9–9.1% and 5.6–8.3% for low [10 ng/mL], medium [50 ng/mL] and high [100 ng/mL] concentration) and recoveries (ranged from 85–97%). Verf.-Referat